BACKGROUND AND OBJECTIVES

The Food and Drug Administration expanded Emergency Use Authorization for use of Pfizer-BioNTech (BNT-162b2) coronavirus disease 2019 vaccine to include people ages 12 years and older on May 10, 2021. We describe adverse events observed during the first full year of the US coronavirus disease 2019 vaccination program for adolescents ages 12 to 17 years.

METHODS

We conducted descriptive analyses using data from 2 complementary US vaccine safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health impacts, and the Vaccine Adverse Event Reporting System (VAERS), the national spontaneous reporting system. We reviewed reports and calculated adverse event reporting rates using vaccine administration data.

RESULTS

Among 172 032 adolescents ages 12 to 17 years enrolled in v-safe, most reported reactions following BNT-162b2 were mild to moderate, most frequently reported on the day after vaccination, and more common after dose 2. VAERS received 20 240 adverse event reports; 91.5% were nonserious. Among adverse events of interest, we verified 40 cases of multisystem inflammation syndrome in children (1.2 cases per million vaccinations), 34 (85%) of which had evidence of prior severe acute respiratory syndrome coronavirus 2 infection; and 570 cases of myocarditis (17.7 cases per million vaccinations), most of whom (77%) reported symptom resolution at the time of report.

CONCLUSIONS

During the first year BNT-162b2 was administered to adolescents ages 12 to 17 years, most reported adverse events were mild and appeared self-limited. Rates of myocarditis were lower than earlier reports. No new serious safety concerns were identified.

What’s Known on This Subject:

Findings from preauthorization clinical trials and early United States monitoring among Pfizer-BioNTech messenger RNA coronavirus disease 2019 vaccine (BNT-162b2) vaccinated adolescents did not identify new or serious safety concerns.

What This Study Adds:

Analyses of Pfizer-BioNTech messenger RNA coronavirus disease 2019 vaccine (BNT-162b2) administration from 2 safety monitoring systems confirm early findings and provide additional information about rare adverse events. Reporting rates of postvaccination myocarditis were lower than those in early reports but remained highest among boys ages 16 to 17 years.

The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech (BNT-162b2) coronavirus disease 2019 (COVID-19) vaccine for use in people ages 16 years and older on December 11, 20201 ; vaccine administration started on December 14. On May 10, 2021, FDA expanded the EUA to include adolescents ages 12 to 15 years2  based on results from a Phase 3 clinical trial.3  The trial found that vaccinees in this age group commonly reported transient mild-to-moderate reactogenicity, primarily injection site pain, fatigue, and headache; no vaccine-related serious adverse events were observed.3  Findings from postauthorization safety monitoring of BNT-162b2 primary series vaccination during the first 3 months of use among adolescents ages 12 to 17 years were generally consistent with safety data observed in preauthorization trials; however, myocarditis was reported more commonly than expected, at 61 to 122 cases per million adolescent boys vaccinated.46  Early v-safe participants in this age group reported local and systemic reactions; fewer than 25% of respondents reported that these reactions interfered with their ability to perform normal daily activities.4  Although reassuring, early reports were limited in their ability to detect adverse events following dose 2, as the risk interval for some adverse events (eg, Guillain-Barre at 42 days or multisystem inflammatory syndrome in children (MIS-C) at 90 days) extended beyond the study period of even those earliest vaccine administrations in this age group.

As of May 10, 2022, 1 year after FDA expanded BNT-162b2 vaccine authorization to include adolescents ages 12 to 17 years, 32 268 525 primary series vaccine doses had been administered to adolescents and 15 493 807 were fully vaccinated with a 2-dose primary series.7  Our objective is to provide a comprehensive safety assessment after 1 year of the BNT-162b2 vaccination program for US adolescents using surveillance data from 2 complementary vaccine safety systems, v-safe and the Vaccine Adverse Event Reporting System (VAERS).

We analyzed data reported to v-safe and VAERS before May 23, 2022 for US adolescents ages 12 to 17 years who received a primary series BNT-162b2 vaccine dose during December 14, 2020 through May 10, 2022. We did not include v-safe and VAERS reports for adolescents ages 12 to 15 years if their recorded vaccination occurred before the EUA expansion on May 10, 2021, when the vaccine was authorized for this age group. The Centers for Disease Control and Prevention (CDC) established v-safe (https://vsafe.cdc.gov) to monitor reactogenicity and health impacts after COVID-19 vaccination. We described daily health surveys completed by v-safe participants in the week after vaccination as previously described (Supplemental Information).8  CDC’s v-safe call center contacts vaccine recipients or a parent or guardian when a health survey indicates a vaccine recipient received medical care after vaccination and encourages completion of a VAERS report if indicated. VAERS is a US passive surveillance system comanaged by the CDC and FDA that accepts reports of adverse events after vaccination from any source, including healthcare providers, vaccine manufacturers, and members of the public.9  The COVID-19 vaccine EUAs and CDC Provider Agreements for the COVID-19 Vaccination Program outline mandatory reporting elements.10  Symptoms, signs, and diagnostic findings in the VAERS reports are assigned Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) by trained staff.11  More than 1 MedDRA PT may be assigned to a report; these terms include symptoms and diagnostic evaluations and do not necessarily correspond to medical diagnoses. VAERS reports are further classified as serious if hospitalization, prolongation of hospitalization, life-threatening illness, permanent disability, congenital anomaly or birth defect, or death are noted by the reporter.12  VAERS staff follow-up on serious reports and reports of selected adverse events to request additional information, including medical records, death certificates, and autopsy reports are obtained death, if available. We identified, reviewed, and adjudicated reports to VAERS of potential MIS-C and myocarditis after receipt of BNT-162b2 by using methods similar to those previously described (Supplemental Information).6,13,14  Other VAERS reports were not clinically reviewed. We calculated crude reporting rates for prespecified adverse events of special interest (AESI) using doses administered through May 10, 2022 as the denominator (Supplemental Information).7 

These surveillance activities were reviewed by CDC and conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.).

In the first year of use under EUA, 15 493 807 adolescents ages 12 to 17 years received at least 1 primary-dose BNT-162b2 vaccine; 172 032 (1.1%) enrolled in v-safe, completing a total of 1 199 763 day 0 to 7 surveys. The median age of participants was 16 years, 54.6% were girls, 62.7% were white, and 73.4% were non-Hispanic or Latino ethnicity (Table 1). Surveys for adolescents ages 12 to 15 were completed by guardians; for those ages 16 to 17, over 97% were completed by the vaccinee. When queried, most registrants reported BNT-162b2 was administered alone, without other concurrent vaccinations (97.0% and 99.0% for dose 1 and 2, respectively). Influenza was the most common vaccine reported to be administered concurrently with BNT-162b2 (Table 2). Approximately one-third (35.7%) of total surveys were completed during May 2021, when the EUA was expanded to include 12 to 15-year-olds.

Participants commonly reported local injection site reactions after both doses, with most respondents reporting reactions on the day after vaccination (Table 3). During the first week, these reports of vaccine reactions decreased each subsequent day. Injection site pain was the most reported local reaction after both doses. Systemic reactions were more frequently reported after dose 2 than dose 1 (52.5% of respondents after dose 1 vs 65.8% after dose 2; P < .0001). Most systemic reactions were reported on the day after vaccination; reporting of systemic reactions decreased over time since vaccination. Fatigue, headache, and myalgia were the most common systemic reactions after each dose. Approximately 4% of respondents reported that they were unable to work or attend school in the week after receiving dose 2, compared with 1.3% who missed work or school because of symptoms after dose 1 (P < .0001). Fewer than 1% of respondents received medical care for symptoms reported in the week following vaccination, regardless of dose received.

Respondents rated the severity of their local and systemic reactions following each vaccine dose based on how the reactions impacted their ability to complete activities of daily living (Table 4). Although the total proportion of respondents reporting local injection site pain was similar after each dose (∼61% after dose 1 or dose 2), the proportion of participants who reported their pain as moderate or severe was higher after dose 2 compared with dose 1 (28.5% vs 21.2%; P < .0001). Similarly, systemic reactions such as fatigue (47.3% vs 30.7%; P < .0001), headache (46.1% vs 27.5%; P < .0001), myalgia (35.0% vs 23.2%; P < .0001), and fever (22.2% vs 7.5%; P < .0001) were more commonly reported generally and more commonly reported as more severe after dose 2 compared with dose 1.

During December 14, 2020 through May 10, 2022, 32 268 525 primary series BNT-162b2 vaccine doses were administered to adolescents ages 12 to 17 years. In that period, VAERS received and processed 20 240 reports of adverse events among adolescents; the median age was 15 years and over half (51.9%) of the reports were for adolescent girls (Table 5). The month with the most reports filed was June 2021 (3690). Most reports indicated BNT-162b2 was administered alone (20 038; 99%); seasonal inactivated influenza vaccine was the most frequently simultaneously administered vaccine (74; 36.6% of reported coadministered vaccines), followed by other routine adolescent vaccinations, including quadrivalent meningococcal, 9-valent HPV, and Tdap (Table 6).

Most VAERS reports were classified as nonserious (18 514; 91.5%) (Table 7). Dizziness (3063; 15.1%) was the most commonly reported adverse event. Systemic reactions known to be associated with the vaccine (headache [2104; 10.4%], pyrexia (fever) [1967; 9.7%], nausea [1912; 9.5%], fatigue [1580; 7.8%], and pain [1163; 5.8%]) were also frequently reported. There were 6089 (30.1%) reports of vaccination errors, including product storage errors (1885; 9.3%), underdoses (934; 4.6%), and product administered to a patient of an inappropriate age (865; 4.3%). Among reports listing a vaccination error, 321 of 6089 (5.3%) also reported an adverse health event; 27 (8.4%) were classified as serious. VAERS received 56 reports of anaphylaxis occurring on the day of or day after vaccination; 63 anaphylaxis cases were reported in the week after vaccination (Table 8). These cases were not reviewed or adjudicated; however, if all 63 reports met the Brighton Collaboration case definition,15  the reporting rate would be 1.95 cases per million vaccine doses administered. There were 501 reports of seizures occurring in the first week following vaccination among adolescents aged 12 to 17 years. Sixty-nine of these reports were classified as serious, and pre-existing seizures were noted in 31 of 69 (44.9%).

From December 14, 2020, through May 10, 2022, 84 potential cases of MIS-C were reported to VAERS among 12 to 17-years-olds within 90 days after receipt of a BNT-162b2 dose (Fig 1) (Supplemental Information). Forty (47.6%) met the 2020 CDC MIS-C case definition; of these, 34 (85.0%) had evidence of past or recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 4 (10.0%) did not have evidence of past or recent SARS-CoV-2 infection, and infection status could not be determined for 2 (5.0%). Thirty-nine of the 40 were discharged from the hospital; 1 case with evidence of past or recent SARS-CoV-2 infection was transferred to a rehabilitation facility.

During the surveillance period, 681 VAERS reports met the search for myocarditis; in 642 we obtained sufficient information from healthcare provider interviews or medical record reviews to apply the CDC case definition. Seventy-two were misclassified or did not meet the case definition for myocarditis; 570 cases were confirmed (17.7 cases per million second doses administered). Most cases (514 of 570; 90.2%) occurred in boys. When stratified by age, sex, and vaccine dose received, adolescent boys ages 16 to 17 years after dose 2 had the highest reporting rate (84.0 cases per million second doses administered) (Table 9). At the time of reporting, 77.0% indicated that they had fully recovered from symptoms of myocarditis. CDC has requested additional follow-up information for cases who reported any continuing symptoms.

We reviewed all available information for the 36 deaths reported to VAERS after vaccination; medical records, death certificates, or autopsy reports were available for 34. Causes of death included complications of malignancy or neoplasm (5); cardiomyopathy associated with genetic, ischemic, or non-COVID-19 infections (5); intracranial bleeding from a ruptured aneurysm or thrombus (without documented thrombocytopenia) (4); pulmonary emboli (4: 1 with chronic lung disease, 1 with bilateral air emboli, 2 with concomitant oral contraceptive use); COVID-19 disease (3); muscular dystrophy (2); myocarditis with an identified infectious agent (2: 1 parvovirus-B19 and 1 SARS-CoV-2); suicide (2); acute hyperglycemic crisis (1); epilepsy (1); metabolic syndrome (1); neuromuscular disorder (1); respiratory illness in a tracheotomy-dependent patient (1); and Clostridium sepsis (1). There was insufficient information to determine a presumptive cause of death for 4 reports. One-third (12 of 36) of the decedents had documentation of complex medical histories, with multiple diagnoses predating COVID-19 vaccination. We observed no apparent pattern or clustering of causes of death. We found no evidence to suggest that vaccination contributed to any reported death.

Using data from 2 complementary surveillance systems, v-safe and VAERS, we review safety surveillance during the first year of BNT-162b2 vaccination among US adolescents ages 12 to 17 years. In that year, over 32 million doses were administered for primary series vaccination and over 15 million adolescents were fully vaccinated.7  Overall, our findings are consistent with earlier reports of adverse events reported by vaccinated US residents in this age group.4,6,13 

The expansion of the BNT-162b2 EUA to include people ages 12 to 15 years coincided with greater US vaccine availability; the greatest number of vaccinations in this age group occurred during May 2021.7  Safety data corresponded with vaccination administration, as v-safe received the most survey responses during May 2021 and VAERS received the most reports during June.

As expected from clinical trial3  and early safety data,4  adolescents experienced both local and systemic reactions following vaccination, with more substantial reactions after dose 2 than dose 1. Most adolescents reported reactions to v-safe on the day following vaccination; reporting steadily decreased during the first week after vaccination, which is consistent with previous reports to v-safe for all age groups.16  Inability to attend work or school in the week following dose 2 (4.1%) was lower than reports among adults (12.3%)16  or children ages 5 to 11 years (10.9%)8  and lower than previously described.4  These differences may be related to changes in policies regarding school attendance, the widespread return to in-person school for the 2021 to 2022 school year, or the effects of circulating virus variants. Reports of receipt of healthcare after vaccination have been low among all age groups.4,8,16 

VAERS accepts all reports of adverse events occurring after vaccination, regardless of biological or clinical plausibility that a reported outcome could be associated with vaccination. Therefore, VAERS reports alone are not used to establish a causal association with vaccination.12  VAERS received reports of 37 deaths after BNT-162b2 vaccination; among 34 reports that included medical or autopsy data, we found no evidence to suggest an association between vaccination and death. During the surveillance period, which included periods of SARS-CoV-2 Δ and ο circulation, we identified 40 reports of MIS-C (1.2 cases per million vaccine doses administered). This rate is similar to the rate reported previously among persons ages 12 to 20 years who received at least 1 BNT-162b2 vaccination through August 31, 2021 (1.0 cases per million people who received at least 1 dose).13  For reports of MIS-C occurring after vaccination, most cases (34 of 38 with complete information) had evidence of prior SARS-CoV-2 infection. Some MIS-C cases in this report were described in the previous report13  and are included here to present a fuller assessment of MIS-C in this age group during the analytic period. The potential contribution of vaccination, if any, to these illnesses is unknown.13  Available data do not suggest an association between BNT-162b2 vaccination and death, and demonstrate that vaccination is the most effective way to prevent MIS-C.17 

Myocarditis is a rare adverse event known to be associated with messenger RNA (mRNA) COVID-19 vaccination; risk is greater among male vaccinees and after dose 2.4,6,1824  Vaccination at present is the most effective approach for preventing cardiac complications related to SARS-CoV-2 infection itself, as the risk of cardiac disease after infection may be 2- to 6-fold higher than after vaccination.25  The myocarditis reporting rate was lower for boys ages 12 to 15 years (48.3 cases per million second doses administered) than boys ages 16 to 17 years (84.0 cases per million second doses). These observations are consistent with previous findings that the peak risk group is boys ages 16 to 17 years, although our myocarditis reporting rates are lower than those in early reports.6  The Vaccine Safety Datalink, a network of 9 US healthcare organizations conducting vaccine safety monitoring, reported a myocarditis incidence rate of 137 cases per million doses administered to boys ages 16 to 17.26  Similar to earlier reports, we found that most myocarditis cases reported to VAERS experienced resolution of symptoms by the time the report was submitted.6  A population-based cohort study found the reporting rate of myocarditis after COVID-19 mRNA vaccination was significantly higher among those who received dose 2 within 30 days of dose 1 compared with those whose doses were separated by 56 days or greater.27  Extending the interval between dose 1 and dose 2 to 8 weeks may reduce the risk of myocarditis in groups at highest risk.25,27 

Simultaneous vaccination with BNT-162b2 and other vaccines among adolescents ages 12 to 17 years was not common; only 1% to 3% of participants in VAERS or v-safe reported that they received a concurrent vaccination. This finding was not unexpected, as the adolescent vaccine schedule includes fewer routine vaccinations than the schedule for younger children. CDC clinical guidance states that COVID-19 vaccines may be administered without regard to timing of other vaccines, including simultaneous administration of COVID-19 vaccine and other vaccines.28 

The findings in this report are subject to several limitations. Data from these 2 surveillance systems may not be representative of the BNT-162b2 vaccinated US population. V-safe is a voluntary program and participants may be more likely to report an adverse event than the general vaccinated population. Some v-safe participants completed surveys for only 1 primary vaccine dose; participants who did not report a second dose may not have received it or may have been lost to follow-up. VAERS data are subject to reporting biases, including underreporting of nonserious events.9  Because VAERS is a passive, numerator-only surveillance system, rates of adverse events generally cannot be calculated directly. However, using COVID-19 doses administered in the US population, reporting rates for adverse events can be estimated, and reporting ratios for adverse events can be used to evaluate disproportional reporting of adverse events for specific vaccines. A vaccinated person could report adverse reactions to both v-safe and VAERS. V-safe collects information on common, expected, and specific reactions. VAERS collects additional data and is designed to serve as a signal detection system for new or rare serious adverse events. For both surveillance systems, disparities in access to smartphone and computer technology may impact reporting. Data collection, including review of myocarditis, MIS-C, and death reports, is ongoing in each system.

The Advisory Committee on Immunization Practices and the American Academy of Pediatrics currently recommend that adolescents ages 12 to 17 years receive a 2-dose primary series of an mRNA COVID-19 vaccine and a bivalent booster >2 months after completed primary series or previously received monovalent booster.2931  After 1 year of EUA administration, ∼60% of adolescents have received a primary COVID-19 vaccine series.7  Our safety findings, collected during the administration of ∼32 million primary series doses of BNT-162b2 vaccine to adolescents ages 12 to 17 years, are consistent with previously reported data. Local and systemic reactions are relatively common; they are usually mild and resolve quickly. Postvaccination myocarditis is a rare complication most commonly reported in boys following dose 2 of an mRNA-based vaccine. We found no new serious safety concerns in the US adolescent population vaccinated with BNT-162b2. Our findings provide additional evidence to support the US COVID-19 vaccination program in adolescents to prevent COVID-19 and its serious complications.

We thank members of the MIS-C Review Group: Lara Akinbami, E. Gloria Anyalechi, Angela Campbell, C. Buddy Creech (Vanderbilt University Medical Center), Kathryn Edwards (Vanderbilt University Medical Center), Satoshi Kamidani (Children’s Healthcare of Atlanta and Emory University School of Medicine), David W. McCormick, Datta Munshi, Oidda Museru, Elizabeth Schlaudecker (University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center), Mary Staat (University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center), Allan Taylor, and Anna Yousaf; and acknowledge Karen Broder for her leadership and support.

A complete list of study group members appears in the Acknowledgments.

Drs Hesse, Hause, Myers, and Shay conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript; Dr. Myers designed the data collection instruments and collected data as well; Dr Su assisted in data acquisition and analysis and reviewed and revised the manuscript; Ms Marquez and Mr Zhang performed data analysis and reviewed and revised the manuscript; Drs Cortese, Thames-Allen, Curtis, and Maloney procured and cleaned data, adjudicated potential MIS-C cases, and reviewed and revised the manuscript; Drs Thompson, Nair, Alimchandani, and Niu provided FDA insight into the study and reviewed and revised the manuscript; Ms Gee assisted with the planning, reviewing, and revision of the manuscript; Dr Shimabukuro conceptualized the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention or Food and Drug Administration.

FUNDING: This work was supported by the Food and Drug Administration and the Centers for Disease Control and Prevention, including the CDC Clinical Immunization Safety Assessment Project contracts 200–2012–50430 to Vanderbilt University Medical Center and 20–012–53661 to Cincinnati Children’s Hospital Medical Center.

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no conflicts of interest relevant to this article to disclose.

BNT-162b2

Pfizer-BioNTech mRNA COVID-19 vaccine

CDC

Centers for Disease Control and Prevention

COVID-19

coronavirus disease 2019

EUA

Emergency Use Authorization

FDA

Food and Drug Administration

MedDRA

Medical Dictionary for Regulatory Activities

MIS-C

multisystem inflammatory syndrome in children

mRNA

messenger ribonucleic acid

PT

preferred terms

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

VAERS

Vaccine Adverse Events Reporting System

1
US Food and Drug Administration
.
Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum (2020)
.
Available at: https://www.fda.gov/media/144416/download. Accessed February 17, 2023
2
US Food and Drug Administration
.
Pfizer-BioNTech COVID-19 vaccine EUA amendment review memorandum (2021)
.
Available at: https://www.fda.gov/media/144412/download. Accessed February 17, 2023
3
Frenck
RW
Jr
,
Klein
NP
,
Kitchin
N
, et al;
C4591001 Clinical Trial Group
.
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
.
N Engl J Med
.
2021
;
385
(
3
):
239
250
4
Hause
AM
,
Gee
J
,
Baggs
J
, et al
.
COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021
.
MMWR Morb Mortal Wkly Rep
.
2021
;
70
(
31
):
1053
1058
5
Shay
DK
,
Shimabukuro
TT
,
DeStefano
F
.
Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines
.
JAMA Cardiol
.
2021
;
6
(
10
):
1115
1117
6
Oster
ME
,
Shay
DK
,
Su
JR
, et al
.
Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021
.
JAMA
.
2022
;
327
(
4
):
331
340
7
US Department of Health and Human Services, CDC
.
COVID data tracker
.
Available at: https://covid.cdc.gov/covid-data-tracker. Accessed May 11, 2022
8
Hause
AM
,
Baggs
J
,
Marquez
P
, et al
.
COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021
.
MMWR Morb Mortal Wkly Rep
.
2021
;
70
(
5152
):
1755
1760
9
Shimabukuro
TT
,
Nguyen
M
,
Martin
D
,
DeStefano
F
.
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
.
Vaccine
.
2015
;
33
(
36
):
4398
4405
10
Centers for Disease Control and Prevention
.
Vaccine Adverse Event Reporting System (VAERS)
.
11
Medical Dictionary for Regulatory Activities
.
MedDRA hierarchy
.
Available at: https://www.meddra.org/how-to-use/basics/hierarchy. Accessed March 07, 2022
12
US Department of Health and Human Services, FDA
.
U. S. code of federal regulations, 21 CFR 600.80 postmarketing reporting of adverse experiences
.
13
Yousaf
AR
,
Cortese
MM
,
Taylor
AW
, et al;
MIS-C Investigation Authorship Group
.
Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation
.
Lancet Child Adolesc Health
.
2022
;
6
(
5
):
303
312
14
Law
B
.
AESI case definition companion guide for 2nd tier AESI: myocarditis and pericarditis
.
15
Law
B
.
AESI case definition companion guide for 1st tier AESI: anaphylaxis
.
16
Rosenblum
HG
,
Gee
J
,
Liu
R
, et al
.
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
.
Lancet Infect Dis
.
2022
;
22
(
6
):
802
812
17
Zambrano
LD
,
Newhams
MM
,
Olson
SM
, et al;
Overcoming COVID-19 Investigators
.
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021
.
MMWR Morb Mortal Wkly Rep
.
2022
;
71
(
2
):
52
58
18
Gargano
JW
,
Wallace
M
,
Hadler
SC
, et al
.
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices - United States, June 2021
.
MMWR Morb Mortal Wkly Rep
.
2021
;
70
(
27
):
977
982
19
Montgomery
J
,
Ryan
M
,
Engler
R
, et al
.
Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military
.
JAMA Cardiol
.
2021
;
6
(
10
):
1202
1206
20
Marshall
M
,
Ferguson
ID
,
Lewis
P
, et al
.
Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination
.
Pediatrics
.
2021
;
148
(
3
):
e2021052478
21
Kim
HW
,
Jenista
ER
,
Wendell
DC
, et al
.
Patients with acute myocarditis following mRNA COVID-19 vaccination
.
JAMA Cardiol
.
2021
;
6
(
10
):
1196
1201
22
Diaz
GA
,
Parsons
GT
,
Gering
SK
,
Meier
AR
,
Hutchinson
IV
,
Robicsek
A
.
Myocarditis and pericarditis after vaccination for COVID-19
.
JAMA
.
2021
;
326
(
12
):
1210
1212
23
Mevorach
D
,
Anis
E
,
Cedar
N
, et al
.
Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel
.
N Engl J Med
.
2021
;
385
(
23
):
2140
2149
24
Witberg
G
,
Barda
N
,
Hoss
S
, et al
.
Myocarditis after Covid-19 vaccination in a large health care organization
.
N Engl J Med
.
2021
;
385
(
23
):
2132
2139
25
Block
JP
,
Boehmer
TK
,
Forrest
CB
, et al
.
Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination - PCORnet, United States, January 2021-January 2022
.
MMWR Morb Mortal Wkly Rep
.
2022
;
71
(
14
):
517
523
26
Shimabukuro
T
.
Update on myocarditis following mRNA COVID-19 vaccination
.
27
Buchan
SA
,
Seo
CY
,
Johnson
C
, et al
.
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada
.
JAMA Netw Open
.
2022
;
5
(
6
):
e2218505
28
Centers for Disease Control and Prevention
.
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States
.
29
Wallace
M
,
Woodworth
KR
,
Gargano
JW
, et al
.
The advisory committee on immunization practices’ interim recommendation for use of Pfizer- BioNTech COVID-19 vaccine in adolescents aged 12-15 years - United States, May 2021
.
MMWR Morb Mortal Wkly Rep
.
2021
;
70
(
20
):
749
752
30
Centers for Disease Control and Prevention
.
CDC expands booster shot eligibility and strengthens recommendations for 12-17 year olds
.
31
Maldonado
Y
,
O’Leary
S
,
Banerjee
R
;
Committee on Infectious Diseases
.
COVID-19 vaccines in children and adolescents
.
Pediatrics
.
2022
;
149
(
1
):
e2021054332

Supplementary data